Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217

JJ Cook, MA Holahan, EA Lyle, DR Ramjit, GR Sitko, MT Stranieri, RF Stupienski , AA Wallace, EL Hand, JR Gehret, T Kothstein, MD Drag, GY McCormick, JJ Perkins, NC Ihle, ME Duggan, GD Hartman, RJ Gould and JJ Lynch

Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania, USA.

The antiplatelet activity of L-734,217, a nonpeptide platelet GPIIb/IIIa antagonist, was evaluated in the rat, guinea pig and dog. IC50 for inhibition of in vitro platelet aggregation for these species (agonists: adenosine diphosphate, collagen) were rat, 838,000 and > 1,100,000 nM; guinea pig, 124 and 156 nM; dog, 42 and 50 nM. In an in vivo rat/in vitro dog platelet aggregation assay, effective antiaggregatory plasma concentrations of L-734,217 were achieved after 8.0 to 16.0 mg/kg p.o. vs. 0.3 to 1.0 mg/kg i.v. to rats. Delays in platelet-dependent hemostatic plug formation in severed mesenteric arteries were observed after 2.0 to 5.0 mg/kg p.o. vs. 0.1 to 0.2 mg/kg i.v. to guinea pigs. Dose-dependent inhibitions of ex vivo platelet aggregation after 0.3 to 3.0 mg/kg p.o. and 0.03 to 0.3 mg/kg i.v. L- 734,217 to conscious dogs yielded estimates of 8 to 16% oral bioavailability. The antiplatelet activity of 3.0 mg/kg p.o. L-734,217 in dogs was unaffected by dosage form or food. In a conscious dog model of left circumflex coronary artery electrolytic lesion, 3.0 mg/kg p.o. L-734,217 q4 to 8 hr reduced thrombus mass, prevented occlusive coronary artery thrombosis and reduced or prevented myocardial infarction and ventricular ectopy. In anesthetized dogs, a dissociation between inhibition of ex vivo platelet aggregation and template bleeding time prolongation was observed with i.v. L-734,217. The results of the coadministration of heparin, aspirin and L-734,217 to anesthetized dogs suggested a synergistic effect on template bleeding time with no effect on plasma L-734,217 concentrations. These findings indicate L-734,217 to be an important lead structure for the development of therapeutically useful oral antiplatelet agents.

Volume 278, Issue 1, pp. 62-73, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. Thibault, P. Tardif, and G. Lapalme Comparative Specificity of Platelet {alpha}IIb{beta}3 Integrin Antagonists J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 690 - 696. [Abstract] [Full Text]

				B. Bednar, J. J. Cook, M. A. Holahan, M. E. Cunningham, P. A. Jumes, R. A. Bednar, G. D. Hartman, and R. J. Gould Fibrinogen Receptor Antagonist-Induced Thrombocytopenia in Chimpanzee and Rhesus Monkey Associated With Preexisting Drug-Dependent Antibodies to Platelet Glycoprotein IIb/IIIa Blood, July 15, 1999; 94(2): 587 - 599. [Abstract] [Full Text] [PDF]

				J. J. Cook, S. J. Gardell, M. A. Holahan, G. R. Sitko, G. L. Stump, A. A. Wallace, D. B. Gilberto, T. R. Hare, J. A. Krueger, D. L. Dyer, et al. Antithrombotic Efficacy of Thrombin Inhibitor L-374,087: Intravenous Activity in a Primate Model of Venous Thrombus Extension and Oral Activity in a Canine Model of Primary Venous and Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 503 - 510. [Abstract] [Full Text]

				R. A. Bednar, S. L. Gaul, T. G. Hamill, M. S. Egbertson, J. A. Shafer, G. D. Hartman, R. J. Gould, and B. Bednar Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1317 - 1326. [Abstract] [Full Text]

				J. J. Cook, G. R. Sitko, M. A. Holahan, M. T. Stranieri, J. D. Glass, B. C. Askew, C. J. McIntyre, D. A. Claremon, J. J. Baldwin, G. D. Hartman, et al. Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic Efficacy of L-738,167, a Long-Acting GPIIb/IIIa Antagonist, Correlates with Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation but not with Bleeding Time Prolongation J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 677 - 689. [Abstract] [Full Text]